Acute asthma associated with sustained-release verapamil

被引:3
|
作者
BenNoun, L [1 ]
机构
[1] BEN GURION UNIV NEGEV,FAC HLTH SCI,DEPT FAMILY MED,IL-84105 BEER SHEVA,ISRAEL
关键词
asthma; verapamil; sustained-release;
D O I
10.1177/106002809703100514
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained-release verapamil. CASE SUMMARY: A 66-year-old white woman with a 10-year history of hypertension and bronchial asthma was switched from immediate-release verapamil hydrocloride 40 mg rid to sustained-release verapamil 240 mg/d po for better hypertension control. After taking the first tablet, she developed dyspnea, cough, and wheezing. Antiasthmatic medications were prescribed, but the asthma symptoms did not improve. She continued taking verapamil for 6 months, then, on her own, stopped all medications including the sustained-release verapamil, and her asthma symptoms disappeared. On rechallenge she developed severe dyspnea, cough, and wheezing 20 minutes after administration. The asthma resolved within 24 hours following three albuterol inhalations. The next day similar symptoms developed with rechallenge of the same brand of sustained-release verapamil in a 120-mg formulation, and verapamil was discontinued. Six months later she was again prescribed sustained-release verapamil 240 mg in another clinic where the physician was unaware of her previous reaction. Once again, severe dyspnea, cough, and wheezing developed. DISCUSSION: On four separate occasions the patient was challenged, advertently or inadvertently, with sustained-release verapamil. Similar symptoms developed after each challenge and resolved after discontinuing this preparation. Although dyspnea associated with verapamil administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release verapamil administration. CONCLUSIONS: Sustained-release verapamil is thought to be the cause of the asthma attack in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation.
引用
收藏
页码:593 / 595
页数:3
相关论文
共 50 条
  • [1] OVERDOSE OF SUSTAINED-RELEASE VERAPAMIL
    RANKIN, RJ
    EDWARDS, IR
    NEW ZEALAND MEDICAL JOURNAL, 1990, 103 (887) : 165 - 165
  • [2] POISONING WITH SUSTAINED-RELEASE VERAPAMIL
    KOZLOWSKI, JH
    KOZLOWSKI, JA
    SCHULLER, D
    AMERICAN JOURNAL OF MEDICINE, 1988, 85 (01): : 127 - 127
  • [3] OVERDOSE OF SUSTAINED-RELEASE VERAPAMIL
    BARROW, PM
    HOUSTON, PL
    WONG, DT
    BRITISH JOURNAL OF ANAESTHESIA, 1994, 72 (03) : 361 - 365
  • [4] SUSTAINED-RELEASE VERAPAMIL IN STABLE ANGINA
    KOHLI, RS
    RODRIGUES, EA
    HUGHES, LO
    LAHIRI, A
    RAFTERY, EB
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1988, 42 (04): : 20 - 23
  • [5] SEVERE VERAPAMIL (SUSTAINED-RELEASE) OVERDOSE
    KRICK, SE
    GUMS, JG
    GRAUER, K
    COOPER, GR
    DICP-THE ANNALS OF PHARMACOTHERAPY, 1990, 24 (7-8): : 705 - 706
  • [6] ANTIHYPERTENSIVE EFFICACY OF SUSTAINED-RELEASE VERAPAMIL
    ZACHARIAH, PK
    SHEPS, SG
    OSHRAIN, C
    SCHIRGER, A
    STEIN, WJ
    JOURNAL OF CLINICAL HYPERTENSION, 1987, 3 (04): : 536 - 546
  • [7] FATAL OVERDOSE WITH SUSTAINED-RELEASE VERAPAMIL
    MACDONALD, D
    ALGUIRE, PC
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1992, 303 (02): : 115 - 117
  • [8] SERIOUS POISONING WITH SUSTAINED-RELEASE VERAPAMIL
    HAGEGE, A
    MASQUET, C
    BEAUFILS, P
    SLAMA, R
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1990, 83 (11): : 1745 - 1747
  • [9] SUSTAINED-RELEASE VERAPAMIL IN RENAL-HYPERTENSION
    EISKJAER, H
    PEDERSEN, EB
    RASMUSSEN, LM
    JESPERSEN, B
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 33 (06) : 549 - 555
  • [10] EFFICACY OF SUSTAINED-RELEASE VERAPAMIL IN THE TREATMENT OF HYPERTENSION
    ZACHARIAH, PK
    SHEPS, SG
    SCHIRGER, A
    JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 25 (06): : 471 - 471